Kiniksa Pharmaceuticals International, plc (KNSA) Operating income 2017–2025
Kiniksa Pharmaceuticals International, plc (KNSA) annual operating income history from SEC filings — each fiscal year as reported.
$77.2MFY2025 · since FY2017: -$65.4M → $77.2M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $77.2M | +269.3% |
| FY2024 | -$45.6M | -81.0% |
| FY2023 | -$25.2M | -357.8% |
| FY2022 | $9.8M | +106.2% |
| FY2021 | -$156.6M | +0.5% |
| FY2020 | -$157.4M | +7.4% |
| FY2019 | -$170.0M | -57.1% |
| FY2018 | -$108.2M | -65.4% |
| FY2017 | -$65.4M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More KNSA financial trends
KNSA RevenueKNSA Net incomeKNSA Net marginKNSA Gross profitKNSA Gross marginKNSA Operating marginKNSA Operating cash flowKNSA Free cash flowKNSA Capital expendituresKNSA Return on equityKNSA Stock buybacksKNSA Dividends paidKNSA Total assetsKNSA Total liabilitiesKNSA Shareholders’ equityKNSA overview →